세계의 mRNA 백신 시장은 2024년에 114억 5,000만 달러로 평가되고, 2030년에는 183억 7,000만 달러에 이를 것으로 예측되며, 예측 기간 중 CAGR은 8.34%를 나타낼 전망입니다.
세계의 mRNA 백신 시장은 COVID-19 백신의 성공과 기술의 잠재력 확대로 촉진된 급속한 성장을 경험하고 있습니다. 예를 들어, 세계보건기구(WHO)에 따르면 심혈관 질환(CVD)은 전 세계 사망 원인 중 가장 큰 비중을 차지하며 연간 약 1,790만 명의 생명을 앗아가고 있습니다. 심혈관 질환은 심장과 혈관 질환을 포함하며, 대부분의 사망은 심근경색과 뇌졸중으로 인해 발생하며, 주로 70세 미만의 사람들에게 영향을 미칩니다.
| 시장 개요 | |
|---|---|
| 예측 기간 | 2026-2030년 |
| 시장 규모 : 2024년 | 114억 5,000만 달러 |
| 시장 규모 : 2030년 | 183억 7,000만 달러 |
| CAGR(2025-2030년) | 8.34% |
| 급성장 부문 | COVID-19 m RNA 백신 |
| 최대 시장 | 북미 |
mRNA 백신은 합성 메신저 RNA를 사용하여 세포에 면역 반응을 유발하는 단백질을 생성하도록 지시합니다. 이 방법은 기존 백신 플랫폼에 비해 개발 및 제조 속도가 빠릅니다. 지속적인 연구로 mRNA가 암 면역 치료, 유전 질환 및 자가 면역 질환에 대한 용도가 탐구됨에 따라 시장은 더 이상 전염병에 국한되지 않습니다. 지질 나노 입자 전달 시스템의 발전으로 mRNA 백신의 안정성과 효율성이 향상되어 치료 혁신의 새로운 기회가 열렸습니다. 기업들은 장기적인 수요를 지원하기 위해 mRNA 연구 파이프라인 및 제조 인프라 확장에 막대한 투자를 하고 있습니다. 규제 기관도 mRNA 기술과 관련된 빠른 개발 속도에 적응하고 있습니다. mRNA 백신에 대한 대중의 인식과 수용이 높아지면서 다양한 지역에서 채택이 더욱 확대되었습니다. 콜드 체인 물류 및 높은 생산 비용과 같은 과제가 남아 있지만, 새로운 업체의 진입과 전략적 협력으로 시장은 계속 발전하고 있습니다. 기술이 성숙함에 따라 mRNA 백신은 표적화되고 개인화된 확장 가능한 의료 솔루션을 제공하며, 최근의 예방 및 치료 의학의 초석으로 자리매김할 것으로 예상됩니다.
신속한 백신 개발에 대한 수요 증가
콜드체인 및 보관 요구 사항
백신 이외의 치료제로의 다양화
Global mRNA Vaccine Market was valued at USD 11.45 billion in 2024 and is expected to reach USD 18.37 Billion by 2030 with a CAGR of 8.34% during the forecast period. The global mRNA Vaccine market has experienced rapid growth driven by the success of COVID-19 vaccines and the expanding potential of the technology. For instance, according to WHO, cardiovascular diseases (CVDs) are the world's leading cause of death, claiming around 17.9 million lives annually. They include heart and blood vessel disorders, with most deaths caused by heart attacks and strokes, often affecting people under 70.
| Market Overview | |
|---|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 11.45 Billion |
| Market Size 2030 | USD 18.37 Billion |
| CAGR 2025-2030 | 8.34% |
| Fastest Growing Segment | COVID-19 m RNA Vaccines |
| Largest Market | North America |
mRNA Vaccines use a synthetic version of messenger RNA to instruct cells to produce proteins that trigger an immune response. This method enables faster development and manufacturing compared to traditional vaccine platforms. The market is no longer limited to infectious diseases, as ongoing research explores mRNA's application in cancer immunotherapy, genetic disorders, and autoimmune conditions. Advancements in lipid nanoparticle delivery systems have improved the stability and efficiency of mRNA Vaccines, opening new opportunities for therapeutic innovation. Companies are investing heavily in expanding mRNA research pipelines and manufacturing infrastructure to support long-term demand. Regulatory agencies are also adapting to accommodate the rapid pace of development associated with mRNA technologies. The rise in public awareness and acceptance of mRNA Vaccines has further boosted adoption across various geographies. While challenges such as cold chain logistics and high production costs remain, the market continues to evolve with new entrants and strategic collaborations. As technology matures, mRNA Vaccines are expected to become a cornerstone of modern preventive and therapeutic medicine, offering targeted, personalized, and scalable healthcare solutions.
Key Market Drivers
Rising Demand for Rapid Vaccine Development
The rising demand for rapid vaccine development is a major force driving the global mRNA Vaccine market. For instance, on 29 July 2024, Bio-Manguinhos/Fiocruz, one of Latin America's largest vaccine manufacturers, joined CEPI's Global South network. This partnership aims to enhance rapid and equitable vaccine responses to emerging infectious diseases by expanding manufacturing capacity across the Latin American and Caribbean region, strengthening preparedness for future epidemic and pandemic threats through localized production and regional collaboration. Traditional vaccine development can take years, involving complex cultivation, inactivation, or protein purification processes. In contrast, mRNA Vaccines can be designed and produced within weeks once a target pathogen's genetic sequence is known. This speed has become crucial in responding to public health emergencies, as demonstrated during the COVID-19 pandemic. Governments, healthcare organizations, and pharmaceutical companies now recognize the importance of having platforms that allow for quick vaccine adaptation and deployment. mRNA technology offers a flexible and programmable approach. By simply changing the mRNA sequence, developers can target new variants or different diseases without overhauling the entire production process. This flexibility allows for rapid response not only to pandemics but also to emerging infectious threats and seasonal outbreaks. The global health landscape is increasingly shaped by unpredictable disease patterns, making rapid vaccine development a strategic priority.
The ability to accelerate vaccine research and approval timelines also aligns with global efforts to strengthen pandemic preparedness. Investments are being directed toward expanding mRNA production infrastructure, streamlining regulatory pathways, and establishing stockpiles of platform technologies. As demand grows for adaptable and efficient vaccine solutions, mRNA platforms are emerging as essential tools in modern immunization strategies.
Key Market Challenges
Cold chain and storage requirements
Cold chain and storage requirements present a significant challenge to the growth and accessibility of the global mRNA Vaccine market. Unlike traditional vaccines that can often be stored at standard refrigeration temperatures, many first-generation mRNA Vaccines require ultra-cold storage conditions, sometimes as low as -70°C. These extreme requirements create logistical hurdles, especially in developing countries or remote regions where ultra-low temperature freezers and reliable electricity are limited or unavailable. Maintaining the cold chain from manufacturing facilities to administration sites demands specialized equipment, constant temperature monitoring, and trained personnel. Any break in this chain can compromise the integrity and efficacy of the vaccine, leading to waste and reduced immunization rates. This complexity increases distribution costs and slows down deployment, particularly during mass vaccination campaigns or emergency responses.
Efforts are being made to develop mRNA Vaccines that are more stable at higher temperatures, which would simplify storage and handling. Some newer formulations have achieved stability at standard refrigeration levels for limited durations, offering hope for wider accessibility. However, such innovations are still under development and not yet broadly available for all mRNA-based products. Until more thermostable solutions become mainstream, the cold chain will remain a critical limiting factor. Addressing this issue is essential for expanding the reach of mRNA Vaccines globally, especially in regions with fragile healthcare infrastructure.
Key Market Trends
Diversification Into Therapeutics Beyond Vaccines
Diversification into therapeutics beyond vaccines is transforming the landscape of the global mRNA Vaccine market. While initial breakthroughs centered on infectious diseases like COVID-19, mRNA technology is now being harnessed for a broad spectrum of therapeutic applications. Oncology is a primary focus, where personalized cancer vaccines use patient-specific tumor mutations to train the immune system to target malignant cells. Companies like BioNTech and Moderna are actively developing clinical programs aimed at various cancers, including melanoma, lung, and pancreatic types.
The appeal of mRNA in oncology lies in its adaptability and speed. Developers can rapidly design and produce vaccines that match an individual's cancer profile, offering a level of customization that traditional therapies cannot provide. This approach not only enhances treatment precision but also opens the door to more effective combination therapies with checkpoint inhibitors or immunomodulators. In genetic disorders, mRNA therapies are being explored as a way to replace faulty or missing proteins. Diseases such as cystic fibrosis or certain metabolic conditions are potential targets, where mRNA could provide temporary yet repeated protein correction. This method offers a less invasive and potentially safer alternative to gene editing technologies. Autoimmune diseases are also emerging as a new frontier. mRNA may help retrain the immune system to tolerate self-antigens, offering novel treatments for conditions like multiple sclerosis or type 1 diabetes. This shift toward broader therapeutic use signals a long-term evolution of the mRNA platform beyond its vaccine origins.
In this report, the Global MRNA Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global MRNA Vaccine Market.
Global MRNA Vaccine Market report with the given Market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report: